In addition, G9a in lung cancer increases H3K9me2 levels at the PTEN promoter to suppress its transcription, thereby activating the AKT signaling pathway and contributing to the development of resistance against EGFR tyrosine kinase inhibitors (EGFR-TKIs). The gene discussed is EGFR; the disease is lung carcinoma.